Vicore Pharma: Smart Money Injection

Research Note

2020-07-03

08:49

Redeye has a positive view on Vicore’s directed share issue of SEK 185 million to Swedish and international investors. Although the issue causes a dilution effect, it has also increased out confidence in the case. Hence, we see no reason to adjust our fair values at this point, and we reiterate our Base case at SEK 48 per share.

LS

Ludvig Svensson

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.